GNPX 2017 Annual Report

92 Any potential payments and benefits due upon a qualifying termination of employment or a change in control are further described below under “—Potential Payments and Benefits upon Termination or Change in Control.” Potential Payments and Benefits upon Termination or Change in Control Regardless of the manner in which a named executive officer’s service terminates, each named executive officer is entitled to receive amounts earned during his term of service, including unpaid salary. In addition, each Mr. Varner, Dr. Pham and Mr. Confer is entitled to receive certain benefits upon our termination of his employment without cause or his resignation for good reason, and Mr. Varner is entitled to receive certain additional benefits upon such a termination or resignation within 12 months after a change of control, all as provided above under “—Agreements with Named Executive Officers.” Each of our named executive officers holds stock options that were granted subject to the general terms and termination and change in control provisions of our 2009 Equity Incentive Plan. Outstanding Equity Awards at Fiscal Year-End The following table sets forth certain information regarding equity awards granted to our named executive officers that were outstanding as of December 31, 2017. Option Awards(1) Name Grant Date Number of securities underlying unexercised option (#) exercisable Number of securities underlying unexercised option (#) unexercisable Option exercise price ($)(2) Option expiration date J. Rodney Varner 4/11/2016 645,572 — $ 0.96 4/11/2026 Julien Pham 11/3/2016 47,483 115,317 (3) $ 5.29 11/3/2026 Ryan Confer 7/25/2012 116,973 — $ 0.01 7/25/2022 4/11/2016 161,396 — $ 0.96 4/11/2026 11/3/2016 86,894 — $ 5.29 11/3/2026 (1) All of the outstanding stock option awards were granted under and subject to the terms of our 2009 Equity Incentive Plan. As of December 31, 2017, each option award becomes exercisable as it becomes vested and all vesting is subject to the executive’s continuous service with us through the vesting dates and the potential vesting acceleration described above under “—Potential Payments and Benefits upon Termination or Change in Control.” (2) All of the stock option awards were granted with a per share exercise price no less than the fair market value of one share of our common stock on the date of grant, as determined in good faith by our board of directors. (3) 3,392 shares will vest each month until October 25, 2020. Perquisites, Health, Welfare and Retirement Benefits Our named executive officers, during their employment with us, are eligible to participate in our employee benefit plans, including our medical, dental, vision, employee whole life, disability and accidental death and dismemberment insurance plans, in each case on the same basis as all of our other employees. We do not provide a 401(k) plan to our employees at this time. We generally do not provide perquisites or personal benefits to our named executive officers, except in limited circumstances. We do, however, pay the premiums for medical, dental, vision, employee whole life, disability and accidental death and dismemberment insurance for all of our employees, including our named executive officers. Our board of directors may elect to adopt qualified or nonqualified benefit plans in the future if it determines that doing so is in our best interests. Director Compensation Historically, we have not paid cash compensation to any of our non-employee directors for service on our board of directors. We did not pay equity compensation to our non-employee directors in 2017 for service on our board of directors. We have reimbursed and will continue to reimburse all of our non-employee directors for their travel, lodging and other reasonable expenses incurred in attending meetings of our board of directors and committees of our board of directors.